| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| Other Sizes |
| Targets |
20(S),24(R)-Ocotillol targets cellular stress response pathways. It modulates cellular stress responses, reduces oxidative damage, and improves mitochondrial function. Its mechanism of action may involve the regulation of antioxidant enzymes and the protection of mitochondria from oxidative damage. It is also likely to interact with signaling pathways involved in cell survival and apoptosis. Its effects on mitochondrial function suggest it may be a modulator of energy metabolism.
|
|---|---|
| ln Vitro |
In vitro, 20(S),24(R)-Ocotillol has been shown to have protective effects on cells by reducing oxidative damage and improving mitochondrial function. It is studied in various cell-based models of cardiovascular and neurological disorders. Its ability to modulate cellular stress responses makes it a valuable tool for studying the mechanisms of cell protection.
|
| ln Vivo |
In vivo, 20(S),24(R)-Ocotillol is being investigated for its potential benefits in cardiovascular and neurological disorders. Its ability to reduce oxidative damage and improve mitochondrial function suggests it could be protective against ischemic injury and neurodegenerative diseases. However, specific in vivo data are not detailed in the provided search results.
|
| Enzyme Assay |
In vitro non-cell enzyme assays for 20(S),24(R)-Ocotillol are not standard. Its effects are typically assessed in cell-based assays. However, its antioxidant activity can be measured using cell-free assays such as DPPH or ABTS.
|
| Cell Assay |
In vitro cell-based assays for 20(S),24(R)-Ocotillol use various cell lines to study its protective effects. Cells are treated with the compound and exposed to an oxidative stressor or other insults. Parameters such as cell viability, ROS levels, and mitochondrial function (e.g., membrane potential, ATP levels) are measured. These studies help to elucidate its mechanism of action.
|
| Animal Protocol |
In vivo animal studies for 20(S),24(R)-Ocotillol would likely employ models of cardiovascular disease (e.g., myocardial infarction) or neurological disorders (e.g., stroke, Parkinson's disease). The compound would be administered, and its effects on infarct size, neurological function, and oxidative stress markers would be assessed.
|
| ADME/Pharmacokinetics |
20(S),24(R)-Ocotillol has a molecular weight of 492.7 g/mol and a molecular formula of C₃₀H₅₂O₅. It is a solid powder. The compound should be stored desiccated at -20°C. Its solubility is typical of triterpenoids.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 20(S),24(R)-Ocotillol is not extensively detailed. As a natural product from Panax ginseng, it is generally considered to have a good safety profile. However, comprehensive toxicological studies are required for therapeutic development. It is not intended for human therapeutic use without further development.
|
| Additional Infomation |
20(S),24(R)-Ocotillol is a triterpenoid from Panax ginseng and other plants. It modulates cellular stress responses, reduces oxidative damage, and improves mitochondrial function. It is used in research on cardiovascular and neurological disorders. It is not approved for clinical use and is intended for research purposes only.
|
| Molecular Formula |
C30H52O5
|
|---|---|
| Molecular Weight |
492.730890274048
|
| Exact Mass |
492.381
|
| CAS # |
69926-31-4
|
| PubChem CID |
15886258
|
| Appearance |
White to off-white solid powder
|
| Density |
1.126±0.06 g/cm3(Predicted)
|
| Boiling Point |
594.5±50.0 °C(Predicted)
|
| LogP |
4.6
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
35
|
| Complexity |
856
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
C[C@]1(CC[C@@H](O1)C(C)(C)O)[C@H]2CC[C@@]3([C@@H]2[C@@H](C[C@H]4[C@]3(C[C@@H]([C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)O)C)O)C
|
| InChi Key |
XIGBHUXQOPWGDK-HTGHARJWSA-N
|
| InChi Code |
InChI=1S/C30H52O5/c1-25(2)21(33)10-12-27(5)20-15-18(31)23-17(30(8)14-11-22(35-30)26(3,4)34)9-13-28(23,6)29(20,7)16-19(32)24(25)27/h17-24,31-34H,9-16H2,1-8H3/t17-,18+,19-,20+,21-,22+,23-,24-,27+,28+,29+,30-/m0/s1
|
| Chemical Name |
(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-17-[(2S,5R)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthrene-3,6,12-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0295 mL | 10.1475 mL | 20.2951 mL | |
| 5 mM | 0.4059 mL | 2.0295 mL | 4.0590 mL | |
| 10 mM | 0.2030 mL | 1.0148 mL | 2.0295 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
